Efficacy data (n = 37)*
| Modafinil (n = 19) | Placebo (n = 18) | |||
|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 1 | Visit 2 | |
| *Data are mean (SD) and 95% confidence intervals. | ||||
| †None of the subsections of the SF-36 significantly improved compared with placebo. | ||||
| All comparisons: p>0.05. | ||||
| UPDRS, Unified Parkinson’s Disease Rating Scale. | ||||
| Epworth Scale | 15.7 (3.1) | 13.5 (4.8) | 16.0 (3.7) | 14.5 (4.8) |
| 14.2 to 17.2 | 11.1 to 15.8 | 14.2 to 17.8 | 12.1 to 16.9 | |
| UPDRS activities of daily living | 12.5 (5.4) | 12.7 (5.6) | 14.2 (6.4) | 14.7 (6.6) |
| 9.9 to 15.1 | 10.1 to 15.5 | 11.0 to 17.4 | 11.4 to 18.0 | |
| UPDRS motor | 23.9 (10.0) | 23.7 (9.5) | 28.8 (9.5) | 28.5 (9.8) |
| 19.1 to 28.7 | 19.1 to 28.2 | 24.1 to 33.6 | 23.6 to 33.4 | |
| Multiple sleep latency test | 6.4 (5.1) | 4.9 (3.6) | 4.5 (3.9) | 4.1 (3.4) |
| (mean minutes) | 3.9 to 8.8 | 3.1 to 6.6 | 2.5 to 6.5 | 2.4 to 5.7 |
| Short Form–36† | 37.6 (14.1) | 36.7 (12.7) | 36.8 (12.8) | 36.9 (12.5) |
| Fatigue Severity Scale | 37.6 (14.1) | 36.8 (12.7) | 36.8 (12.8) | 37.8 (10.8) |
| 30.8 to 44.4 | 30.7 to 42.9 | 30.4 to 43.2 | 32.4 to 43.1 | |
| Hamilton Depression Scale | 6.5 (5.0) | 5.5 (4.6) | 7.2 (5.2) | 5.6 (4.0) |
| 4.1 to 8.9 | 3.3 to 7.8 | 4.6 to 9.8 | 3.6 to 7.6 | |
| Change in sleepiness “much or very much improved” | 6/19 (32%) | 4/18 (22%) | ||